 | • レポートコード：GIR201100235 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、アダリムマブの世界市場を調査対象にし、アダリムマブの市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（アダリムマブ、アダリムマブバイオシミラー）、用途別分析（大人、子供）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：AbbVie、Boehringer Ingelheim、Amgen、Sandoz、Biogen、Mylan ・メーカー別販売量、売上、市場シェア ・アダリムマブの地域別市場分析 ・アダリムマブの北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・アダリムマブのヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・アダリムマブのアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・アダリムマブの南米市場規模2015-2020：ブラジル、アルゼンチンなど ・アダリムマブの中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・アダリムマブの種類別市場規模2015-2020：アダリムマブ、アダリムマブバイオシミラー ・アダリムマブの用途別市場規模2015-2020：大人、子供 ・アダリムマブの世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Adalimumab market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Adalimumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Adalimumab market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Adalimumab market has been segmented into
Adalimumab
Adalimumab Biosimilar
By Application, Adalimumab has been segmented into:
Adults
Children
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Adalimumab market presented in the report. This section sheds light on the sales growth of different regional and country-level Adalimumab markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Adalimumab market.
The report offers in-depth assessment of the growth and other aspects of the Adalimumab market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Adalimumab Market Share Analysis
Adalimumab competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Adalimumab sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Adalimumab sales, revenue and market share for each player covered in this report.
The major players covered in Adalimumab are:
AbbVie
Boehringer Ingelheim
Amgen
Sandoz
Biogen
Mylan
Among other players domestic and global, Adalimumab market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adalimumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Adalimumab, with price, sales, revenue and global market share of Adalimumab in 2018 and 2019.
Chapter 3, the Adalimumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Adalimumab market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Adalimumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Adalimumab Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Adalimumab Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Adalimumab
1.2.3 Adalimumab Biosimilar
1.3 Market Analysis by Application
1.3.1 Overview: Global Adalimumab Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Adults
1.3.3 Children
1.4 Overview of Global Adalimumab Market
1.4.1 Global Adalimumab Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AbbVie SWOT Analysis
2.1.4 AbbVie Product and Services
2.1.5 AbbVie Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Boehringer Ingelheim SWOT Analysis
2.2.4 Boehringer Ingelheim Product and Services
2.2.5 Boehringer Ingelheim Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Amgen SWOT Analysis
2.3.4 Amgen Product and Services
2.3.5 Amgen Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Sandoz
2.4.1 Sandoz Details
2.4.2 Sandoz Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Sandoz SWOT Analysis
2.4.4 Sandoz Product and Services
2.4.5 Sandoz Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Biogen
2.5.1 Biogen Details
2.5.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Biogen SWOT Analysis
2.5.4 Biogen Product and Services
2.5.5 Biogen Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Mylan
2.6.1 Mylan Details
2.6.2 Mylan Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Mylan SWOT Analysis
2.6.4 Mylan Product and Services
2.6.5 Mylan Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Adalimumab Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Adalimumab Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Adalimumab Manufacturer Market Share in 2019
3.3.2 Top 6 Adalimumab Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Adalimumab Sales, Revenue and Market Share by Regions
4.1.1 Global Adalimumab Sales and Market Share by Regions (2015-2020)
4.1.2 Global Adalimumab Revenue and Market Share by Regions (2015-2020)
4.2 North America Adalimumab Sales and Growth Rate (2015-2020)
4.3 Europe Adalimumab Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Adalimumab Sales and Growth Rate (2015-2020)
4.5 South America Adalimumab Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Adalimumab Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Adalimumab Sales, Revenue and Market Share by Country
5.1.1 North America Adalimumab Sales and Market Share by Country (2015-2020)
5.1.2 North America Adalimumab Revenue and Market Share by Country (2015-2020)
5.2 United States Adalimumab Sales and Growth Rate (2015-2020)
5.3 Canada Adalimumab Sales and Growth Rate (2015-2020)
5.4 Mexico Adalimumab Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Adalimumab Sales, Revenue and Market Share by Country
6.1.1 Europe Adalimumab Sales and Market Share by Country (2015-2020)
6.1.2 Europe Adalimumab Revenue and Market Share by Country (2015-2020)
6.2 Germany Adalimumab Sales and Growth Rate (2015-2020)
6.3 UK Adalimumab Sales and Growth Rate (2015-2020)
6.4 France Adalimumab Sales and Growth Rate (2015-2020)
6.5 Russia Adalimumab Sales and Growth Rate (2015-2020)
6.6 Italy Adalimumab Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Adalimumab Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Adalimumab Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Adalimumab Revenue and Market Share by Regions (2015-2020)
7.2 China Adalimumab Sales and Growth Rate (2015-2020)
7.3 Japan Adalimumab Sales and Growth Rate (2015-2020)
7.4 Korea Adalimumab Sales and Growth Rate (2015-2020)
7.5 India Adalimumab Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Adalimumab Sales and Growth Rate (2015-2020)
7.7 Australia Adalimumab Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Adalimumab Sales, Revenue and Market Share by Country
8.1.1 South America Adalimumab Sales and Market Share by Country (2015-2020)
8.1.2 South America Adalimumab Revenue and Market Share by Country (2015-2020)
8.2 Brazil Adalimumab Sales and Growth Rate (2015-2020)
8.3 Argentina Adalimumab Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Adalimumab Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Adalimumab Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Adalimumab Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Adalimumab Sales and Growth Rate (2015-2020)
9.3 Turkey Adalimumab Sales and Growth Rate (2015-2020)
9.4 Egypt Adalimumab Sales and Growth Rate (2015-2020)
9.5 South Africa Adalimumab Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Adalimumab Sales and Market Share by Type (2015-2020)
10.2 Global Adalimumab Revenue and Market Share by Type (2015-2020)
10.3 Global Adalimumab Price by Type (2015-2020)
11 Global Adalimumab Market Segment by Application
11.1 Global Adalimumab Sales Market Share by Application (2015-2020)
11.2 Global Adalimumab Revenue Market Share by Application (2015-2020)
11.3 Global Adalimumab Price by Application (2015-2020)
12 Market Forecast
12.1 Global Adalimumab Sales, Revenue and Growth Rate (2021-2025)
12.2 Adalimumab Market Forecast by Regions (2021-2025)
12.2.1 North America Adalimumab Market Forecast (2021-2025)
12.2.2 Europe Adalimumab Market Forecast (2021-2025)
12.2.3 Asia-Pacific Adalimumab Market Forecast (2021-2025)
12.2.4 South America Adalimumab Market Forecast (2021-2025)
12.2.5 Middle East & Africa Adalimumab Market Forecast (2021-2025)
12.3 Adalimumab Market Forecast by Type (2021-2025)
12.3.1 Global Adalimumab Sales Forecast by Type (2021-2025)
12.3.2 Global Adalimumab Market Share Forecast by Type (2021-2025)
12.4 Adalimumab Market Forecast by Application (2021-2025)
12.4.1 Global Adalimumab Sales Forecast by Application (2021-2025)
12.4.2 Global Adalimumab Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Adalimumab Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Adalimumab by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Adalimumab Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. AbbVie Basic Information, Manufacturing Base and Competitors
Table 8. AbbVie Adalimumab Major Business
Table 9. AbbVie Adalimumab Total Revenue (USD Million) (2018-2019)
Table 10. AbbVie SWOT Analysis
Table 11. AbbVie Adalimumab Product and Services
Table 12. AbbVie Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 14. Boehringer Ingelheim Adalimumab Major Business
Table 15. Boehringer Ingelheim Adalimumab Total Revenue (USD Million) (2018-2019)
Table 16. Boehringer Ingelheim SWOT Analysis
Table 17. Boehringer Ingelheim Adalimumab Product and Services
Table 18. Boehringer Ingelheim Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Amgen Basic Information, Manufacturing Base and Competitors
Table 20. Amgen Adalimumab Major Business
Table 21. Amgen Adalimumab Total Revenue (USD Million) (2018-2019)
Table 22. Amgen SWOT Analysis
Table 23. Amgen Adalimumab Product and Services
Table 24. Amgen Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Sandoz Basic Information, Manufacturing Base and Competitors
Table 26. Sandoz Adalimumab Major Business
Table 27. Sandoz Adalimumab Total Revenue (USD Million) (2018-2019)
Table 28. Sandoz SWOT Analysis
Table 29. Sandoz Adalimumab Product and Services
Table 30. Sandoz Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Biogen Basic Information, Manufacturing Base and Competitors
Table 32. Biogen Adalimumab Major Business
Table 33. Biogen Adalimumab Total Revenue (USD Million) (2018-2019)
Table 34. Biogen SWOT Analysis
Table 35. Biogen Adalimumab Product and Services
Table 36. Biogen Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Mylan Basic Information, Manufacturing Base and Competitors
Table 38. Mylan Adalimumab Major Business
Table 39. Mylan Adalimumab Total Revenue (USD Million) (2018-2019)
Table 40. Mylan SWOT Analysis
Table 41. Mylan Adalimumab Product and Services
Table 42. Mylan Adalimumab Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Global Adalimumab Sales by Manufacturer (2018-2019) (K Units)
Table 44. Global Adalimumab Revenue by Manufacturer (2018-2019) (USD Million)
Table 45. Global Adalimumab Sales by Regions (2015-2020) (K Units)
Table 46. Global Adalimumab Sales Market Share by Regions (2015-2020)
Table 47. Global Adalimumab Revenue by Regions (2015-2020) (USD Million)
Table 48. North America Adalimumab Sales by Countries (2015-2020) (K Units)
Table 49. North America Adalimumab Sales Market Share by Countries (2015-2020)
Table 50. North America Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 51. North America Adalimumab Revenue Market Share by Countries (2015-2020)
Table 52. Europe Adalimumab Sales by Countries (2015-2020) (K Units)
Table 53. Europe Adalimumab Sales Market Share by Countries (2015-2020)
Table 54. Europe Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 55. Asia-Pacific Adalimumab Sales by Regions (2015-2020) (K Units)
Table 56. Asia-Pacific Adalimumab Sales Market Share by Regions (2015-2020)
Table 57. Asia-Pacific Adalimumab Revenue by Regions (2015-2020) (USD Million)
Table 58. South America Adalimumab Sales by Countries (2015-2020) (K Units)
Table 59. South America Adalimumab Sales Market Share by Countries (2015-2020)
Table 60. South America Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 61. South America Adalimumab Revenue Market Share by Countries (2015-2020)
Table 62. Middle East & Africa Adalimumab Sales by Countries (2015-2020) (K Units)
Table 63. Middle East & Africa Adalimumab Sales Market Share by Countries (2015-2020)
Table 64. Middle East & Africa Adalimumab Revenue by Countries (2015-2020) (USD Million)
Table 65. Middle East & Africa Adalimumab Revenue Market Share by Countries (2015-2020)
Table 66. Global Adalimumab Sales by Type (2015-2020) (K Units)
Table 67. Global Adalimumab Sales Share by Type (2015-2020)
Table 68. Global Adalimumab Revenue by Type (2015-2020) (USD Million)
Table 69. Global Adalimumab Revenue Share by Type (2015-2020)
Table 70. Global Adalimumab Sales by Application (2015-2020) (K Units)
Table 71. Global Adalimumab Sales Share by Application (2015-2020)
Table 72. Global Adalimumab Sales Forecast by Regions (2021-2025) (K Units)
Table 73. Global Adalimumab Market Share Forecast by Regions (2021-2025)
Table 74. Global Adalimumab Sales Forecast by Type (2021-2025) (K Units)
Table 75. Global Adalimumab Market Share Forecast by Type (2021-2025)
Table 76. Global Adalimumab Sales Forecast by Application (2021-2025)
Table 77. Global Adalimumab Market Share Forecast by Application (2021-2025)
Table 78. Direct Channel Pros & Cons
Table 79. Indirect Channel Pros & Cons
Table 80. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Adalimumab Picture
Figure 2. Global Sales Market Share of Adalimumab by Type in 2019
Figure 3. Adalimumab Picture
Figure 4. Adalimumab Biosimilar Picture
Figure 5. Adalimumab Sales Market Share by Application in 2018
Figure 6. Adults Picture
Figure 7. Children Picture
Figure 8. Global Adalimumab Market Status and Outlook (2015-2025) (USD Million)
Figure 9. United States Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 10. Canada Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Mexico Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Germany Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 13. France Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 14. UK Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Russia Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Italy Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 17. China Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Japan Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Korea Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 20. India Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Southeast Asia Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Australia Adalimumab Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 23. Brazil Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Egypt Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Saudi Arabia Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 26. South Africa Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Turkey Adalimumab Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Global Adalimumab Sales Market Share by Manufacturer in 2019
Figure 29. Global Adalimumab Revenue Market Share by Manufacturer in 2019
Figure 30. Top 3 Adalimumab Manufacturer (Revenue) Market Share in 2019
Figure 31. Top 6 Adalimumab Manufacturer (Revenue) Market Share in 2019
Figure 32. Key Manufacturer Market Share Trend
Figure 33. Global Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 34. Global Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 35. Global Adalimumab Revenue Market Share by Regions (2015-2020)
Figure 36. Global Adalimumab Revenue Market Share by Regions in 2018
Figure 37. North America Adalimumab Sales and Growth Rate (2015-2020)
Figure 38. Europe Adalimumab Sales and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Adalimumab Sales and Growth Rate (2015-2020)
Figure 40. South America Adalimumab Sales and Growth Rate (2015-2020)
Figure 41. Middle East & Africa Adalimumab Sales and Growth Rate (2015-2020)
Figure 42. North America Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 43. North America Adalimumab Sales Market Share by Countries (2015-2020)
Figure 44. North America Adalimumab Sales Market Share by Countries in 2018
Figure 45. North America Adalimumab Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 46. North America Adalimumab Revenue Market Share by Countries in 2018
Figure 47. United States Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 48. Canada Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 49. Mexico Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Europe Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 51. Europe Adalimumab Revenue Market Share by Countries (2015-2020)
Figure 52. Europe Adalimumab Revenue Market Share by Countries in 2019
Figure 53. Germany Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 54. UK Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 55. France Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 56. Russia Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 57. Italy Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Asia-Pacific Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 59. Asia-Pacific Adalimumab Sales Market Share by Regions 2019
Figure 60. Asia-Pacific Adalimumab Revenue Market Share by Regions 2019
Figure 61. China Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Japan Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Korea Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 64. India Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Southeast Asia Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 66. South America Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 67. South America Adalimumab Sales Market Share by Countries in 2019
Figure 68. South America Adalimumab Revenue Market Share by Countries in 2019
Figure 69. Brazil Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 70. Argentina Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Middle East and Africa Adalimumab Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. Middle East and Africa Adalimumab Sales Market Share by Countries in 2019
Figure 73. Middle East and Africa Adalimumab Revenue Market Share by Countries (2015-2020)
Figure 74. Middle East and Africa Adalimumab Revenue Market Share by Countries in 2019
Figure 75. Saudi Arabia Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 76. Egypt Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Turkey Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 78. South Africa Adalimumab Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Global Adalimumab Sales and Growth Rate (2021-2025) (K Units)
Figure 80. Global Adalimumab Revenue and Growth Rate (2021-2025) (USD Million)
Figure 81. North America Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 82. Europe Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 83. Asia-Pacific Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 84. South America Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 85. Middle East & Africa Sales Adalimumab Market Forecast (2021-2025) (K Units)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
全身型若年性特発性関節炎（JIA）治療の世界市場 2020年 Market Overview The global Systemic Idiopathic Juvenile Arthritis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. …- ベーチェット病治療薬の世界市場 2020年 Market Overview The global Behcet Disease Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Behcet Disease Drug marke…
- 多関節若年性特発性関節炎薬の世界市場 2020年 Market Overview The global Polyarticular Juvenile Idiopathic Arthritis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. …
- 腫瘍壊死因子阻害薬の世界市場 2020年 Market Overview The global Tumor Necrosis Factor Inhibitors Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tumor N…
- バイオシミラー薬品の世界市場 2020年 Market Overview The Biosimilar Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…